In turn, activation of this pathway can inhibit the anti-tumour function of the same immune cells, thereby reducing anti-tumour immunity.26,33–36 However, the effect of the PD-1/PD-L1 interaction on tumour cells has rarely been reported. The gene discussed is PDCD1; the disease is neoplasm.